CONTRATOS DE INVESTIGACIÓN. ART. 83
Contract
Evaluation of anti-CD160 antibodies in "in vivo" models.
Funder: ELSALYS BIOTECH
Call: (ELSALYS BIOTECH)
date_range
Duration: from 11 March 2019 to 10 March 2020
(11 months)
Finished
€1,304.35
Of European scope.
Evaluation of anti-CD160 antibodies in "in vivo" models.
Researchers
Mª LUISA DEL
RÍO GONZÁLEZ
Leader
Publications related to the project
Show by type2023
2022
-
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection
Translational Research